NASDAQ:SPRY ARS Pharmaceuticals (SPRY) Stock Forecast, Price & News $6.62 -0.20 (-2.93%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$6.62▼$7.0250-Day Range$4.52▼$9.0952-Week Range$3.68▼$9.65Volume552,500 shsAverage Volume4.01 million shsMarket Capitalization$627.38 millionP/E RatioN/ADividend YieldN/APrice Target$13.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media ARS Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside106.4% Upside$13.67 Price TargetShort InterestBearish7.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.07Based on 4 Articles This WeekInsider TradingSelling Shares$724,600 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.75) to ($0.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.91 out of 5 starsMedical Sector623rd out of 981 stocksPharmaceutical Preparations Industry306th out of 485 stocks 3.5 Analyst's Opinion Consensus RatingARS Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.67, ARS Pharmaceuticals has a forecasted upside of 106.4% from its current price of $6.62.Amount of Analyst CoverageARS Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.65% of the float of ARS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverARS Pharmaceuticals has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldARS Pharmaceuticals does not currently pay a dividend.Dividend GrowthARS Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SPRY. Previous Next 2.2 News and Social Media Coverage News SentimentARS Pharmaceuticals has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ARS Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest10 people have searched for SPRY on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows3 people have added ARS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ARS Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $724,600.00 in company stock.Percentage Held by Insiders34.40% of the stock of ARS Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ARS Pharmaceuticals are expected to decrease in the coming year, from ($0.75) to ($0.82) per share.Price to Book Value per Share RatioARS Pharmaceuticals has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ARS Pharmaceuticals (NASDAQ:SPRY) StockARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.Read More Receive SPRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRY Stock News HeadlinesJune 5, 2023 | americanbankingnews.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells $496,801.20 in StockJune 2, 2023 | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 4.8%June 8, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 23, 2023 | americanbankingnews.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) to Post Q2 2023 Earnings of ($0.19) Per Share, Wedbush ForecastsMay 20, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for ARS Pharmaceuticals, Inc. Issued By SVB Leerink (NASDAQ:SPRY)May 20, 2023 | americanbankingnews.comARS Pharmaceuticals, Inc. Forecasted to Post Q2 2023 Earnings of ($0.22) Per Share (NASDAQ:SPRY)May 18, 2023 | markets.businessinsider.comWedbush Keeps Their Buy Rating on ARS Pharmaceuticals (SPRY)May 15, 2023 | finance.yahoo.comARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal SprayJune 8, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 15, 2023 | msn.comARS Pharmaceuticals: Potential Revolution In Allergy Treatment With NeffyMay 15, 2023 | finance.yahoo.comARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial ResultsMay 12, 2023 | wsj.comARS Pharmaceuticals Inc.May 12, 2023 | markets.businessinsider.comFDA Panel Votes In Favor Of ARS Pharma's Neffy For Allergic Reactions TreatmentMay 12, 2023 | markets.businessinsider.comWhy ARS Pharmaceuticals Stock Is Soaring TodayMay 12, 2023 | marketwatch.comARS Pharmaceuticals Soar 68% in Premarket Trading as FDA Panel Backs Neffy >SPRYMay 12, 2023 | americanbankingnews.comLaura Shawver Sells 42,900 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockMay 12, 2023 | seekingalpha.comFDA advisors endorse benefits of ARS Pharma epinephrine nasal sprayMay 11, 2023 | finance.yahoo.comFDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including AnaphylaxisMay 10, 2023 | businesswire.comINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmMay 9, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYMay 9, 2023 | msn.comARS Pharma down 12% on FDA AdCom docs for epinephrine nasal sprayMay 9, 2023 | markets.businessinsider.comFDA Issues Some Concerns Regarding ARS Pharma's Investigational Allergy TreatmentMay 9, 2023 | finance.yahoo.comARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including AnaphylaxisApril 28, 2023 | americanbankingnews.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) to Post Q1 2023 Earnings of ($0.13) Per Share, SVB Leerink ForecastsApril 26, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Veru (VERU) and ARS Pharmaceuticals (SPRY)April 25, 2023 | markets.businessinsider.comSVB Securities Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)April 21, 2023 | finance.yahoo.comCompanies Like ARS Pharmaceuticals (NASDAQ:SPRY) Are In A Position To Invest In GrowthSee More Headlines SPRY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SPRY Company Calendar Last Earnings5/15/2023Today6/08/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SPRY CUSIPN/A CIK1671858 Webars-pharma.com Phone206-456-2900FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$13.67 High Stock Price Forecast$17.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+106.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34,680,000.00 Net MarginsN/A Pretax Margin-6,299.11% Return on Equity-15.70% Return on Assets-15.17% Debt Debt-to-Equity RatioN/A Current Ratio27.17 Quick Ratio27.18 Sales & Book Value Annual Sales$1.32 million Price / Sales475.29 Cash FlowN/A Price / Cash FlowN/A Book Value$2.90 per share Price / Book2.28Miscellaneous Outstanding Shares94,770,000Free Float62,172,000Market Cap$627.38 million OptionableOptionable Beta-0.17 Key ExecutivesMr. Richard Lowenthal M.B.A. (Age 56)M.S., MSMSEL, Founder, Pres, CEO & Director Dr. Sarina Tanimoto M.B.A. (Age 54)M.D., Co-Founder & Chief Medical Officer Dr. Robert Bell Ph.D.Co-Founder & Chief Science OfficerMs. Kathleen D. Scott CPAChief Financial OfficerMr. Brian T. Dorsey M.S.SVP of Operations & Project ManagementMr. Daniel RelovskySr. VP of MarketingMr. Harris Kaplan M.B.A. (Age 70)MBA, Exec. VP of Commercial Strategy Mr. Eric Karas (Age 50)Chief Commercial Officer Mr. Justin Chakma (Age 33)Chief Bus. Officer & Sec. More ExecutivesKey CompetitorsHarrow HealthNASDAQ:HROWTyra BiosciencesNASDAQ:TYRAEdgewise TherapeuticsNASDAQ:EWTXTerns PharmaceuticalsNASDAQ:TERNTheravance BiopharmaNASDAQ:TBPHView All CompetitorsInsiders & InstitutionsLaura ShawverSold 73,059 sharesTotal: $496,801.20 ($6.80/share)Prelude Capital Management LLCBought 15,053 shares on 6/1/2023Ownership: 0.016%Royce & Associates LPBought 303,900 shares on 5/23/2023Ownership: 0.321%Ameriprise Financial Inc.Bought 280,329 shares on 5/22/2023Ownership: 0.296%SR One Capital Management LPBought 4,012,903 shares on 5/19/2023Ownership: 4.234%View All Insider TransactionsView All Institutional Transactions SPRY Stock - Frequently Asked Questions Should I buy or sell ARS Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ARS Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRY shares. View SPRY analyst ratings or view top-rated stocks. What is ARS Pharmaceuticals' stock price forecast for 2023? 3 brokerages have issued 12-month price targets for ARS Pharmaceuticals' stock. Their SPRY share price forecasts range from $10.00 to $17.00. On average, they predict the company's stock price to reach $13.67 in the next twelve months. This suggests a possible upside of 106.4% from the stock's current price. View analysts price targets for SPRY or view top-rated stocks among Wall Street analysts. How have SPRY shares performed in 2023? ARS Pharmaceuticals' stock was trading at $8.53 at the beginning of 2023. Since then, SPRY stock has decreased by 22.4% and is now trading at $6.62. View the best growth stocks for 2023 here. When is ARS Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our SPRY earnings forecast. How were ARS Pharmaceuticals' earnings last quarter? ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) posted its quarterly earnings results on Monday, May, 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01. The company had revenue of $0.02 million for the quarter. What ETFs hold ARS Pharmaceuticals' stock? ETFs with the largest weight of ARS Pharmaceuticals (NASDAQ:SPRY) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), IQ Chaikin U.S. Small Cap ETF (CSML), Invesco DWA SmallCap Momentum ETF (DWAS), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), What is ARS Pharmaceuticals' stock symbol? ARS Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPRY." Who are ARS Pharmaceuticals' major shareholders? ARS Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include SR One Capital Management LP (4.23%), Baker BROS. Advisors LP (2.12%), Geode Capital Management LLC (0.43%), Royce & Associates LP (0.32%), Ameriprise Financial Inc. (0.30%) and Jane Street Group LLC (0.15%). Insiders that own company stock include Kathleen D Scott and Laura Shawver. View institutional ownership trends. How do I buy shares of ARS Pharmaceuticals? Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ARS Pharmaceuticals' stock price today? One share of SPRY stock can currently be purchased for approximately $6.62. How much money does ARS Pharmaceuticals make? ARS Pharmaceuticals (NASDAQ:SPRY) has a market capitalization of $627.38 million and generates $1.32 million in revenue each year. How can I contact ARS Pharmaceuticals? ARS Pharmaceuticals' mailing address is 500 Fairview Ave N Suite 600, Seattle WA, 98109. The official website for the company is ars-pharma.com. The company can be reached via phone at 206-456-2900 or via email at ir@silverbacktx.com. This page (NASDAQ:SPRY) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.